In a rodent model of traumatic brain injury, it was shown not only that EPO must be administered in high doses when applied peripherally and that intravenous is superior to intraperitoneal administration but also that rhEPO crosses the BBB with a delay of approximately 4 h and appears to develop its biological effect after around 8 h [1]. The gene discussed is EPO; the disease is brain injury.